Gyre Therapeutics has submitted a Form S-3 registration statement to the U.S. Securities and Exchange Commission to facilitate the sale of shares associated with the full acquisition of Cullgen. Currently, our holdings of Gyre shares are approximately 70%, and there is no expected impact on consolidated earnings.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-06-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/2160-20260624-01.pdf","jir_short_summary":"Gyre Therapeutics has submitted a Form S-3 registration statement to the U.S. Securities and Exchange Commission to facilitate the sale of shares associated with the full acquisition of Cullgen. Currently, our holdings of Gyre shares are approximately 70%, and there is no expected impact on consolidated earnings.","jir_summary":"### Overview of Capital Policy and Stock Registration\nOur consolidated subsidiary, Gyre Therapeutics, has submitted a Form S-3 registration statement to the U.S. Securities and Exchange Commission. This procedure is related to the sale of shares following the full acquisition of Cullgen Inc. completed in May 2026. This submission is not intended as a new fundraising effort by Gyre but is a preparatory step to facilitate share sales. Currently, our effective ownership of Gyre shares is approximately 70%, and our holding policy remains unchanged.\n\n### Outlook and Impact\nWe do not anticipate any significant impact on our consolidated financial results from this matter. The share sale procedures for Gyre may contribute to improved stock liquidity and capital efficiency for shareholders and investors, but at this stage, the sale amount and schedule have not been disclosed. Going forward, we will continue to promote appropriate capital policies while monitoring Gyre\u2019s management situation.","jir_financial_highlights":"Gyre Shareholding Ratio: Approximately 70% (Unknown)\nEffective holding in Gyre shares: Unknown (Unknown)","jir_category":"","jir_hashtags":"#GNIGroup, #IRRelated, #JapaneseStocks","jir_key_figures":"Gyre Shareholding Ratio: approximately 70%\nForm S-3 submission date of Gyre Therapeutics: June 23, 2026\nComplete date of consolidation of subsidiary: May 7, 2026","jir_meta_title":"\u3010GNI Group\u3011Gyre Stock Registration Procedures\uff5cJune 2026","jir_meta_description":"GNI Group\u2019s consolidated subsidiary Gyre Therapeutics has submitted a Form S-3 registration statement to the U.S. Securities and Exchange Commission. This report explains the preparations for stock sales and future outlook.","jir_og_title":"\u3010GNI Group\u3011Gyre Stock Registration Procedures\uff5cJune 2026","jir_og_description":"Gyre Therapeutics has completed stock registration in the U.S. Now attention is focused on future share sales and capital policy trends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-67892","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n